Skip to main content

Advertisement

Log in

Clinical Heterogeneity and Outcomes of Antisynthetase Syndrome

  • INFLAMMATORY MUSCLE DISEASE (I LUNDBERG, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The autoimmune connective tissue disease antisynthetase syndrome (ASS) is an inflammatory myopathy associated with myositis-specific autoantibodies, e.g. anti-tRNA-synthetase antibodies (ASA). Since 1976 eight different ASA have been rigorously identified, of which anti-hystidyl-tRNA synthetase (anti-Jo1) is the most prevalent. Other phenotype features of ASS include interstitial lung disease (ILD), Raynaud’s phenomenon, polyarthritis, fever, and mechanic’s hands. The clinical presentation of ASS varies greatly, as does the severity of involvement of different organs—both among patients and/or over the course of the disease. ILD has been associated with poor outcomes, but in general the heterogeneity of ASS prevents identification of robust prognosis indicators. Early identification of patients requiring aggressive immunosuppressive treatment is very challenging, and there are very few prospective trials available to help match treatment management to ASS clinical characteristics. This review will focus on the biological, clinical, functional, and morphological features of ASS associated with patient outcome. Our objective is to use compiled data on these subjects to discuss the usefulness of patient stratification in developing future prospective therapeutic trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ASS:

Anti-synthetase syndrome

ASA:

Anti-synthetase antibody

ILD:

Interstitial lung disease

SSc:

Systemic sclerosis

SS:

Sjögren syndrome

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019–38.

    Article  PubMed  CAS  Google Scholar 

  2. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360–74.

    CAS  Google Scholar 

  3. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125–31.

    Article  PubMed  CAS  Google Scholar 

  4. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138:1464–74.

    Article  PubMed  Google Scholar 

  5. •• Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12:210–7. Largest study of patients with ASS, revealing different clinical features among patients with ASS according to ASA specificity.

    Article  PubMed  CAS  Google Scholar 

  6. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14:275–85.

    Article  PubMed  CAS  Google Scholar 

  7. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633–8.

    Article  PubMed  Google Scholar 

  8. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282–6.

    Article  CAS  Google Scholar 

  9. •• Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135:1550–6. First large study of patients with anti-PL12-ASS, showing a low prevalence of ILD compared with historical studies of anti-Jo1 ASS.

    Article  PubMed  CAS  Google Scholar 

  10. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739–45.

    Article  PubMed  CAS  Google Scholar 

  11. • Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, Dankó K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91:206–11. Largest study of patients with anti-PL7-ASS suggesting their association with pericarditis.

    Article  CAS  Google Scholar 

  12. Ascherman DP. Animal models of inflammatory myopathy. Curr Rheumatol Rep. 2012;14:257–63.

    Article  PubMed  CAS  Google Scholar 

  13. Soejima M, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum. 2011;63:479–87.

    Article  PubMed  CAS  Google Scholar 

  14. Park SG, Kim HJ, Min YH, Choi E-C, Shin YK, Park B-J, et al. Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. Proc Natl Acad Sci USA. 2005;102:6356–61.

    Article  PubMed  CAS  Google Scholar 

  15. Ascherman DP, Oriss TB, Oddis CV, Wright TM. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol. 2002;169:7127–34.

    PubMed  CAS  Google Scholar 

  16. Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E, et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis. 2012;71:961–5.

    Article  PubMed  CAS  Google Scholar 

  17. Eloranta M-L, Barbasso Helmers S, Ulfgren A-K, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112–24.

    Article  PubMed  CAS  Google Scholar 

  18. Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68:836–43.

    Article  PubMed  Google Scholar 

  19. Lundberg IE, Helmers SB. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity. 2010;43:239–43.

    Article  PubMed  CAS  Google Scholar 

  20. Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14:264–74.

    Article  PubMed  CAS  Google Scholar 

  21. Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589–97.

    Article  PubMed  CAS  Google Scholar 

  22. Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford). 2002;41:1268–72.

    Article  CAS  Google Scholar 

  23. Wasicek CA, Reichlin M, Montes M, Raghu G. Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med. 1984;76:538–44.

    Article  PubMed  CAS  Google Scholar 

  24. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007;19:523–9.

    Article  PubMed  Google Scholar 

  25. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48:607–12.

    Article  CAS  Google Scholar 

  26. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal J-L. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.

    Article  PubMed  Google Scholar 

  27. Rönnelid J, Barbasso Helmers S, Storfors H, Grip K, Rönnblom L, Franck-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9:58–61.

    Article  PubMed  Google Scholar 

  28. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010;49:2370–4.

    Article  CAS  Google Scholar 

  29. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 2006;54:2004–9.

    Article  PubMed  CAS  Google Scholar 

  30. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992;35:821–30.

    Article  PubMed  CAS  Google Scholar 

  31. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford). 2007;46:842–5.

    Article  CAS  Google Scholar 

  32. Chinoy H, Lamb JA, Ollier WER, Cooper RG. Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther. 2011;13:216.

    Article  PubMed  Google Scholar 

  33. •• Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8:R13. This study shows for the firts time correlations between the immune genetic susceptibility (eg. Human Leukocyte Antigen class I & II molecules) and the ASS clinical spectrum.

  34. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.

    Article  PubMed  CAS  Google Scholar 

  35. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol. 1997;109:32–40.

    Article  PubMed  CAS  Google Scholar 

  36. Stanciu R, Guiguet M, Musset L, Touitou D, Beigelman C, Rigolet A, et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol. 2012;39:1835–9.

    Article  PubMed  Google Scholar 

  37. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29:989–94.

    Article  PubMed  Google Scholar 

  38. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39:249–53.

    Article  PubMed  Google Scholar 

  39. • Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard J-F, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012;41:890–9. Study of patients with ASS suggesting the link between anti-SSA/La 52 kDa and the occurrence of cancers.

    Article  PubMed  CAS  Google Scholar 

  40. Park C-K, Kim T-J, Cho Y-N, Kim I-S, Lee H-J, Lee K-E, et al. Development of antisynthetase syndrome in a patient with rheumatoid arthritis. Rheumatol Int. 2011;31:529–32.

    Article  PubMed  Google Scholar 

  41. O’Neill TW, Maddison PJ. Rheumatoid arthritis associated with myositis and anti-Jo-1 antibody. J Rheumatol. 1993;20:141–3.

    PubMed  Google Scholar 

  42. Cavagna L, Fusetti C, Montecucco C, Caporali R. Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome. J Rheumatol. 2010;37:1967. author reply 1968.

    Article  PubMed  Google Scholar 

  43. Schmidt WA, Wetzel W, Friedländer R, Lange R, Sörensen HF, Lichey HJ, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies–an evolving spectrum of disease manifestations. Clin Rheumatol. 2000;19:371–7.

    Article  PubMed  CAS  Google Scholar 

  44. • Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, et al. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013;92:15–24. Histological study analysing retrospectively the pathological features of patients with myositides, including ASS, and showing a high prevalence of dermatomyositic pattern in patients with various ASA.

    Article  Google Scholar 

  45. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatr. 2000;68:472–8.

    Article  PubMed  CAS  Google Scholar 

  46. Aggarwal R, Oddis CV. Therapeutic approaches in myositis. Curr Rheumatol Rep. 2011;13:182–91.

    Article  PubMed  CAS  Google Scholar 

  47. Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Senécal J-L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84:231–49.

    Article  Google Scholar 

  48. Váncsa A, Gergely L, Ponyi A, Lakos G, Németh J, Szodoray P, et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine. 2010;77:125–30.

    Article  PubMed  Google Scholar 

  49. •• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24. Largest prospective trial of patients with myositides testing the clinical efficacy of anti-CD20 monoclonal antibodies on muscle recovery. This study revealed significant reduction of ASA titre after B cell depletion.

    Article  PubMed  CAS  Google Scholar 

  50. Harris-Love MO. Safety and efficacy of submaximal eccentric strength training for a subject with polymyositis. Arthritis Rheum. 2005;53:471–4.

    Article  PubMed  Google Scholar 

  51. Alexanderson H, Lundberg IE. The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2005;17:164–71.

    Article  PubMed  Google Scholar 

  52. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459–67.

    Article  PubMed  CAS  Google Scholar 

  53. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63:53–9.

    Article  PubMed  CAS  Google Scholar 

  54. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238–47.

    Article  PubMed  Google Scholar 

  55. Fischer A, Swigris JJ, Du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103:1719–24.

    Article  PubMed  Google Scholar 

  56. Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity. 2006;39:243–7.

    Article  PubMed  CAS  Google Scholar 

  57. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J. 2011;41:674–9.

    Article  PubMed  CAS  Google Scholar 

  58. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–41.

    Article  PubMed  CAS  Google Scholar 

  59. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183–92.

    Article  PubMed  CAS  Google Scholar 

  60. Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev. 2012;11:335–40.

    Article  PubMed  Google Scholar 

  61. Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti-jo1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2012.

  62. Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.

    Article  PubMed  Google Scholar 

  63. MacDonald SL, Rubens MB, Hansell DM, Copley SJ, Desai SR, Du Bois RM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology. 2001;221:600–5.

    Article  PubMed  CAS  Google Scholar 

  64. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64.

    Article  Google Scholar 

  65. Yousem SA, Gibson K, Kaminski N, Oddis CV, Ascherman DP. The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod Pathol. 2010;23:874–80.

    Article  PubMed  CAS  Google Scholar 

  66. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677–85.

    Article  PubMed  Google Scholar 

  67. • Hervier B, Meyer A, Dieval C, Uzunhan Y, Devilliers H, Launay D, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, etiology and survival. Eur Respir J 2013. This retrospective study shows that pulmonary hypertension is a severe complication of ASS-ILD, which must be better diagnosed.

  68. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46:124–30.

    Article  CAS  Google Scholar 

  69. Hervier B, Masseau A, Mussini J-M, Audrain M, Hamidou MA. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine. 2009;76:575–6.

    Article  PubMed  Google Scholar 

  70. Jankowska M, Butto B, Debska-Slizień A, Rutkowski B. Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int. 2007;27:775–80.

    Article  PubMed  Google Scholar 

  71. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–46.

    Article  PubMed  CAS  Google Scholar 

  72. Marie I, Dominique S, Janvresse A, Levesque H, Menard J-F. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106:581–7.

    Article  PubMed  CAS  Google Scholar 

  73. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968–71.

    Article  CAS  Google Scholar 

  74. Frikha F, Rigolet A, Behin A, Fautrel B, Herson S, Benveniste O. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;48:1166–8.

    Article  CAS  Google Scholar 

  75. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.

    Article  PubMed  CAS  Google Scholar 

  76. Meyer O, Charlanne H, Cherin P, Allanore Y, Coquerelle P, Grardel B, et al. Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann Rheum Dis. 2009;68:152–3.

    Article  PubMed  CAS  Google Scholar 

  77. Oddis CV, Medsger Jr TA, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 1990;33:1640–5.

    Article  PubMed  CAS  Google Scholar 

  78. Queiro-Silva R, Bañegil I, De Dios-Jiménez de Aberásturi JR, Belzunegui-Otano J, González-Beneitez C, Figueroa-Pedrosa M. Periarticular calcinosis associated with anti-Jo-1 antibodies sine myositis. Expanding the clinical spectrum of the antisynthetase syndrome. J Rheumatol. 2001;28:1401–4.

    PubMed  CAS  Google Scholar 

  79. Yang C-J, Sheu C-C, Ou T-T, Hwang J-J, Huang M-S. Combined lung fibrosis and “mechanic’s hand”: a clinical diagnostic clue to amyopathic antisynthetase syndrome. Respirology. 2008;13:611–4.

    Article  PubMed  Google Scholar 

  80. Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55:791–8.

    Article  PubMed  Google Scholar 

  81. Lega J-C, Cottin V, Fabien N, Thivolet-Béjui F, Cordier J-F. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37:1000–9.

    Article  PubMed  CAS  Google Scholar 

  82. Bachmeyer C, Tillie-Leblond I, Lacert A, Cadranel J, Aractingi S. “Mechanic’s hands”: a misleading cutaneous sign of the antisynthetase syndrome. Br J Dermatol. 2007;156:192–4.

    Article  PubMed  CAS  Google Scholar 

  83. Barbasso Helmers S, Englund P, Engström M, Ahlin E, Fathi M, Janciauskiene S, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009;60:2524–30.

    Article  PubMed  Google Scholar 

  84. Hervier B, Lambert M, Hachulla E, Musset L, Benveniste O, Piette J-C, et al. Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren’s syndrome. Rheumatology (Oxford). 2011;50:1175–6.

    Article  Google Scholar 

  85. Mercer LK, Moore TL, Chinoy H, Murray AK, Vail A, Cooper RG, et al. Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2010;49:1699–705.

    Article  Google Scholar 

  86. Mugii N, Hasegawa M, Matsushita T, Hamaguchi Y, Horie S, Yahata T, et al. Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology (Oxford). 2011;50:1091–8.

    Article  Google Scholar 

  87. Riccieri V, Vasile M, Macri V, Sciarra I, Stefanantoni K, De Luca N, et al. Successful immunosuppressive treatment of dermatomyositis: a nailfold capillaroscopy survey. J Rheumatol. 2010;37:443–5.

    Article  PubMed  Google Scholar 

  88. Selva-O’Callaghan A, Fonollosa-Pla V, Trallero-Araguás E, Martínez-Gómez X, Simeon-Aznar CP, Labrador-Horrillo M, et al. Nailfold capillary microscopy in adults with inflammatory myopathy. Semin Arthritis Rheum. 2010;39:398–404.

    Article  PubMed  Google Scholar 

  89. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32–8.

    Article  PubMed  CAS  Google Scholar 

  90. Hervier B, Uzunhan Y, Hachulla E, Benveniste O, Nunes H, Delaval P, et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J. 2011;37:714–7.

    Article  PubMed  CAS  Google Scholar 

  91. Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49:972–6.

    Article  CAS  Google Scholar 

  92. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35–42.

    Article  Google Scholar 

  93. Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007;66:1345–9.

    Article  PubMed  Google Scholar 

  94. Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol. 2005;23:609–15.

    PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Baptiste Hervier declares that he has no conflict of interest.

Olivier Benveniste declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Baptiste Hervier.

Additional information

This article is part of the Topical Collection on Inflammatory Muscle Disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hervier, B., Benveniste, O. Clinical Heterogeneity and Outcomes of Antisynthetase Syndrome. Curr Rheumatol Rep 15, 349 (2013). https://doi.org/10.1007/s11926-013-0349-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0349-8

Keywords

Navigation